<DOC>
	<DOCNO>NCT01690559</DOCNO>
	<brief_summary>This study post-marketing surveillance Japan investigate safety especially focus injection site adverse event efficacy patient Ciprofloxacin iv administration without dilution daily practice.It local prospective observational study patient receive Ciproxan intravenously sepsis , secondary skin infection follow superficial burn , post-surgical post-traumatic , pneumonia , peritonitis , cholecystitis , cholangitis , anthrax . A total 500 patient enrol assessed period treatment Ciproxan .</brief_summary>
	<brief_title>Ciprofloxacin Special Drug Use Investigation - To Investigate Safety Efficacy Patients With Ciprofloxacin iv Administration Without Dilution</brief_title>
	<detailed_description />
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>The mentioned bellow patient cause follow bacteria sensitive drug : Indicated microorganism : Staphylococcus , Enterococcus , Bacillus anthracis , Escherichia coli , Klebsiella , Enterobacter , Pseudomonas aeruginosa , Legionella . Indications : Sepsis , Secondary skin infection ( superficial burn , operative wound , trauma ) , Pneumonia , Peritonitis , Cholecystitis , Cholangitis , Anthrax The patient treat drug without dilution due strict restriction fluid intake . In hospitalized patient retain consciousness , time able report ( vascular pain ) side effects.. Patients contraindicate base product label .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>sepsis</keyword>
	<keyword>infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>peritonitis</keyword>
	<keyword>cholecystitis</keyword>
	<keyword>cholangitis</keyword>
	<keyword>anthrax</keyword>
</DOC>